m+Medelevator.RU
← Поиск публикаций
Respiratory medicine · 2025

Development and validation of a cross-linked sodium hyaluronate based pig model for obstructive sleep apnea.

СтатьяВалидационное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Shang Jiang, Ma Xiaoxiao, Xin Zhijun, Zhang Shaoxing, Li Ruya

Аннотация

OBJECTIVE: This study aims to establish a novel, safe, and reversible animal model of obstructive sleep apnea (OSA) consistent with the pathophysiology of OSA and to investigate the relationship between upper airway obstruction and associated respiratory inflammatory responses.

METHODS: A novel technique involving precise multipoint injection of a cross-linked sodium hyaluronate mixture into the pharynx and palate of adult male Bama pigs via the oral cavity was employed to induce upper airway obstruction. Polysomnography (PSG) and computed tomography (CT) assessed the model's efficacy. Histopathology and enzyme-linked immunosorbent assay (ELISA) analyzed tissue responses and inflammatory markers.

RESULTS: PSG and CT confirmed upper airway obstruction and OSA events in the model pigs. Upper airway volume and cross-sectional area increased over time, reducing AHI events. The injected mixture showed gradual absorption and biosafety. Histopathological examination showed tissue response to OSA at different locations in the respiratory tract, including hyperkeratosis of the pharyngeal squamous epithelium and thickening of alveolar septa. Serum HIF-1α and IL-6 significantly increased 2 days post-injection. AHI correlated with upper airway minimum cross-sectional area, upper airway volume, HIF-1α, and TNF-α.

CONCLUSION: A reversible, safe, and reliable pig model of OSA was successfully established, providing a robust platform for future OSA research and therapeutic exploration.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты